Prezcobix

darunavir/cobicistat (DRV/COBI)

Recommended as component of initial regimen in certain clinical situations
Protease Inhibitor

Standard Dose

One tablet (800 mg of the PI darunavir boosted by 150 mg cobicistat) once daily with food, in people with no darunavir-associated drug resistance, including both treatment-experienced individuals and those who are treatment-naïve (taking HIV therapy for the first time). Must be taken in combination with another antiretroviral(s) which does not contain the medications in this drug or medication from the same drug classes. Use with non-nucleosides or other protease inhibitors is not recommended.

Prezcobix is only available for people taking darunavir once daily, not those who require darunavir twice daily. It is not recommended to co-administer Prezcobix with tenofovir disoproxil fumarate (brand name Viread, found in Truvada), with creatinine clearance (CrCl) less than 70 mL/min (a measure of kidney function).

Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. Prezcobix is not recommended during pregnancy due to substantially lower exposures of darunavir and cobicistat during pregnancy. Cobicistat has not been studied in individuals under 18 years of age, thus Prezcobix should not be used in pediatric patients. Do not use in people with severe liver impairment.

Manufacturer

Janssen Therapeutics
prezcobix.com
(800) JANSSEN (526-7736)

AWP

$2,317.55/month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments